気管支炎:治療薬開発パイプライン分析

◆英語タイトル:Bronchitis - Pipeline Review, H2 2017
◆商品コード:GMDHC9759IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年9月30日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における気管支炎の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・気管支炎の概要
・気管支炎治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・気管支炎パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・気管支炎治療薬開発に取り組んでいる企業:企業別製品パイプライン
・気管支炎治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Bronchitis – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bronchitis – Pipeline Review, H2 2017, provides an overview of the Bronchitis (Respiratory) pipeline landscape.

Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked, shortness of breath aggravated by exertion or mild activity, frequent respiratory infections that worsen symptom, wheezing, fatigue, ankle that affects both sides and headaches. Risk factors include smoking, low resistance and gastric reflux.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bronchitis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bronchitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2, 2 and 3 respectively.

Bronchitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchitis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchitis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchitis (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchitis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchitis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchitis – Overview
Bronchitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bronchitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchitis – Companies Involved in Therapeutics Development
Advanced Inhalation Therapies (AIT) Ltd
AstraZeneca Plc
DBV Technologies SA
F. Hoffmann-La Roche Ltd
Han Wha Pharma Co Ltd
Kyorin Pharmaceutical Co Ltd
Merck & Co Inc
Mucosis BV
Orbis Biosciences Inc
Therabron Therapeutics Inc
Bronchitis – Drug Profiles
alteplase – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-9668 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-367 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclosporine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-051 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lascufloxacin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YJP-40 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchitis – Dormant Projects
Bronchitis – Discontinued Products
Bronchitis – Product Development Milestones
Featured News & Press Releases
Jan 23, 2017: Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings
Feb 03, 2014: AIT To Present Noxcurebr At The Annual Meeting Of The Israeli Association Of Clinical Pediatrics
Jan 19, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants
Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bronchitis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Bronchitis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2017
Bronchitis - Pipeline by AstraZeneca Plc, H2 2017
Bronchitis - Pipeline by DBV Technologies SA, H2 2017
Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Bronchitis - Pipeline by Han Wha Pharma Co Ltd, H2 2017
Bronchitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Bronchitis - Pipeline by Merck & Co Inc, H2 2017
Bronchitis - Pipeline by Mucosis BV, H2 2017
Bronchitis - Pipeline by Orbis Biosciences Inc, H2 2017
Bronchitis - Pipeline by Therabron Therapeutics Inc, H2 2017
Bronchitis - Dormant Projects, H2 2017
Bronchitis - Dormant Projects, H2 2017 (Contd..1), H2 2017
Bronchitis - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Bronchitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

【レポートのキーワード】

気管支炎

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[気管支炎:治療薬開発パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆